Terns Pharmaceuticals(TERN) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 8, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinica ...